C-Peptide Blood Test: Normal, High & Low Levels Explained

C-peptide is a small fragment your pancreas releases at the same time as insulin, in exactly equal amounts. Measuring it is therefore an indirect but reliable way to gauge how much insulin your own body is making — what clinicians call endogenous insulin secretion. The C-peptide blood test is most useful for telling type 1 diabetes from type 2, sizing up how much insulin-making capacity is left, and sorting out the cause of low blood sugar. This guide covers normal C-peptide levels, what high and low results mean, and why C-peptide has nothing to do with a "sugar level." It is always read alongside your blood glucose, and often next to insulin and A1c.

Key takeaways

• C-peptide is released by pancreatic beta cells in equal amounts to insulin (1-to-1), making it the best measure of endogenous insulin secretion.¹
• Its big advantage: it is not affected by injected (exogenous) insulin and has a longer half-life than insulin — so it reflects beta-cell function even in a person treated with insulin.¹²
• A common fasting reference is ~0.5–2.0 ng/mL (≈ 0.17–0.66 nmol/L) — read together with the glucose drawn at the same time, and varying by lab.³⁴
• A low or undetectable C-peptide points toward type 1 diabetes (a pancreas no longer making enough insulin); normal or high points toward type 2 diabetes or insulin resistance.²⁵
• In a low-blood-sugar work-up, a high C-peptide suggests an insulinoma (an insulin-making tumor), whereas a low C-peptide with high insulin suggests injected insulin.¹⁶
• C-peptide is not a cancer marker and not a sugar test: it speaks to insulin production by your pancreas.

What is C-peptide?

To make insulin, the pancreatic beta cells first build a larger molecule called proinsulin. As it is secreted, proinsulin is split in two: on one side, insulin (the hormone that moves sugar into your cells); on the other, C-peptide (the "connecting peptide" that once linked the two insulin chains). Because they come from the same molecule, insulin and C-peptide enter the blood in equal amounts, molecule for molecule.¹

That one-to-one relationship is what makes C-peptide so useful. Measuring it estimates how much insulin the pancreas is actually secreting. C-peptide also has two advantages over measuring insulin directly:

• it is cleared more slowly (a half-life of roughly 20–30 minutes versus a few minutes for insulin), so its level is steadier and more representative;¹
• most importantly, it receives no contribution from injected insulin — insulin therapy delivers only insulin, never C-peptide. In a treated person, C-peptide therefore measures only what their own pancreas still makes.²

C-peptide is not glucose. C-peptide does not measure your sugar level. It measures your pancreas's ability to make insulin. For sugar, that's blood glucose and A1c.

Why the test is done

C-peptide is not a routine test. Your clinician orders it in targeted situations, where it helps to know how much insulin the pancreas still makes:¹²

• Classifying diabetes when the type isn't obvious: telling type 1 (insulin deficiency) from type 2 (insulin present but poorly used), or flagging less common forms (latent autoimmune diabetes in adults, monogenic diabetes).⁵⁷
• Assessing insulin reserve in a person with diabetes: is there enough of their own production left? This helps decide whether to start insulin or adjust treatment.
• Working up unexplained low blood sugar (hypoglycemia): measured during an episode — often in a supervised fasting test — it helps show whether the low is driven by too much of the body's own insulin (insulinoma) or by insulin from outside.¹
• Before certain treatment decisions, or in trials aimed at preserving beta cells.

Outside these situations, ordering it adds little: it is not a screening test for diabetes (that's the job of blood glucose and A1c), and it isn't something to repeat without a reason.

How the test is done

C-peptide is usually measured fasting (typically 8–12 hours), and always with a glucose drawn at the same time — a C-peptide only makes sense once you know the sugar level at that moment. Sometimes the clinician wants a stimulated value (a test meal) or a level taken during a supervised fasting test for hypoglycemia. Follow the exact instructions on your order.¹⁸ If your clinician is sorting out the type of diabetes, expect glucose and often insulin to be measured alongside it. See also Do you need to fast before a blood test?

Normal ranges

Below are indicative adult reference values for fasting C-peptide. They vary by lab and assay, and should never be read alone: it's the pair C-peptide + simultaneous glucose that carries meaning. Always compare against the range printed on your report.⁹

Units: C-peptide is reported in ng/mL or nmol/L. To convert, 1 ng/mL ≈ 0.33 nmol/L. Exact cutoffs differ between labs, and a "low" C-peptide only means something if glucose is normal or high at the same time (a C-peptide that is appropriately low during a hypoglycemic episode means something different).³⁴ Only your clinician can interpret the number in your context.

Understanding your results

High C-peptide

A high C-peptide means the pancreas is making a lot of insulin. The most common causes:²¹

• Insulin resistance and type 2 diabetes — the body compensates by pumping out more insulin, often with excess weight and metabolic syndrome;
• Kidney disease — because C-peptide is cleared by the kidneys, reduced filtration raises it. This is an important interpretation caveat, unrelated to how the pancreas is working;¹
• More rarely, an insulinoma — this small pancreatic tumor makes insulin and C-peptide in an uncontrolled way, causing low blood sugar with a C-peptide that is inappropriately high for the glucose level.¹

C-peptide and cancer? A high C-peptide is not a screening tumor marker. Insulinoma exists, but it is a rare cause of hypoglycemia, looked for in a specific context — not a "sign of cancer" to fear from an isolated number.

Low C-peptide

A low or undetectable C-peptide means the pancreas is no longer making enough insulin. That is the signature of type 1 diabetes (autoimmune destruction of the beta cells) and, more broadly, of any severe insulin deficiency.⁵²¹⁰ An undetectable C-peptide confirms an absolute need for insulin, whatever the initial clinical picture.⁴

Watch for the factitious hypoglycemia trap: in someone secretly injecting insulin, glucose falls and blood insulin is high, but C-peptide stays low — because injected insulin brings no C-peptide. This mismatch (high insulin, low C-peptide) is exactly what distinguishes it from an insulinoma.¹⁶

The C-peptide – insulin – glucose trio

C-peptide is never interpreted alone. It's the cross-reading with blood glucose and insulin that guides your clinician:

• high glucose + low C-peptide → insulin deficiency (type 1);
• high glucose + normal or high C-peptide → insulin resistance / type 2;
• low blood sugar + high C-peptide → inappropriate insulin secretion (insulinoma);
• low blood sugar + high insulin but low C-peptide → exogenous (injected) insulin.

That's why it's often ordered with these two tests and read in light of your A1c and your history.²

What affects your C-peptide

Several things move C-peptide beyond beta-cell function itself: the glucose at the moment (higher sugar stimulates more secretion), kidney function (kidney disease raises it), whether you are fasting or fed, any stimulation (a test meal), and the lab's assay — methods are not yet perfectly harmonized, so values don't always compare across labs.⁴¹ Tell your clinician about your medications (especially insulin and some diabetes drugs) and when you last ate: both change the interpretation.

Recent research

According to recent PubMed-indexed publications:

• Residual C-peptide matters, even in type 1. Type 1 diabetes was long assumed to mean no insulin at all. In fact, many patients keep a residual secretion detectable by C-peptide, and preserving it lowers the risk of complications — which is why C-peptide has become a key endpoint in trials aiming to protect beta cells.⁴¹¹
• Teplizumab, the first therapy to delay type 1 diabetes. This anti-CD3 monoclonal antibody was shown to delay the onset of type 1 diabetes in at-risk relatives (the At-Risk trial, NCT01030861) by preserving beta-cell function measured with C-peptide.¹²¹¹ In a phase 3 trial in newly diagnosed type 1 diabetes (the PROTECT study), treatment maintained higher C-peptide levels than placebo, confirming better preservation of insulin secretion.¹³
• Better diabetes classification. C-peptide is emerging as a simple tool to refine the classification of diabetes, especially in adults — where type 1 is often mistaken for type 2. As many as one in three cases of adult-onset type 1 may be misclassified at first, and C-peptide testing remains underused for setting the diagnosis straight.⁵²
• Toward more reliable results. International standardization efforts aim to harmonize C-peptide measurements across labs — a prerequisite for comparing results and using shared cutoffs in practice.⁴

These findings concern diagnosis and research; they do not authorize self-medication and do not replace your physician's advice.

Get your C-peptide interpreted by AI DiagMe

A C-peptide level is never read alone: its meaning depends on your simultaneous blood glucose, your insulin, your A1c, your kidney function, and your medications. That cross-reading is what gives the result its real value.

👉 AI DiagMe interprets your lab results — blood, urine, or stool — in plain language, taking your whole profile into account. An informational service that does not provide a diagnosis and complements, never replaces, your physician.

Frequently asked questions

Bottom line

C-peptide is released by the pancreas in equal amounts to insulin — so measuring it measures your own body's insulin production. Its key strength is staying reliable even on insulin therapy, because injected insulin brings no C-peptide. Keep the ballpark in mind (~0.5–2.0 ng/mL fasting, lab-dependent, read with glucose), remember that a low C-peptide points toward type 1 diabetes and a high one toward type 2 or insulin resistance, and that it helps untangle low blood sugar (insulinoma vs injected insulin). It is not a sugar test and not a cancer marker. No value is read alone — it's your whole set of markers and your context that counts, which is what AI DiagMe provides, alongside your physician.

Sources

Official U.S. sources and peer-reviewed publications (PubMed, ClinicalTrials.gov) used for this guide: